Ramakrishnan Geethakumari P, Schiewer MJ, Knudsen KE, Kelly WK. PARP Inhibitors in Prostate Cancer. Curr Treat Options in Oncol. 2017;18(6):37.Ramakrishnan Geethakumari, P.; Schiewer, M.J.; Knudsen, K.E.; Kelly, W.K. PARP inhibitors in prostate cancer. Curr. Treat. Opt. Oncol. ...
PARP inhibitors as a new therapeutic option in metastatic prostate cancer: a systematic review A great number of DNA-damage repair (DDR) pathways have been recognized to be frequently dysregulated in advanced stages of prostate cancer. DNA-repair defects in prostate cancer represents a clinically rel...
PARP inhibitors: the race is on. Br J Cancer. 2016;114(7):713–5. doi:10.1038/bjc.2016.67. Article CAS PubMed PubMed Central Google Scholar Helleday T. PARP inhibitor receives FDA breakthrough therapy designation in castration resistant prostate cancer: beyond germline BRCA mutations. Ann ...
home/oncview/parp-inhibitors-in-prostate-cancer Part 1: Oliver Sartor, MD, gives an overview of the use of PARP inhibitors to treat metastatic castration-resistant prostate cancer. Part 2: Alicia Morgans, MD, MPH, discuses the importance of PARP inhibitors in the treatment of metastatic prostat...
突变或未知应突变使用PARP 抑制剂治疗，取决于单独 NHT治疗的早期进展的危险因素，并且需与患者进行共同决策 原文阅读：https://www.urotoday.com/conference-highlights/eau-2024/eau-2024-prostate-cancer/151067-eau-2024-parp-inhibitors-only-for-patients-with-alterations-in-dna-repair-genes-no.html ...
PARP inhibitors (PARPi) are transforming the current treatment landscape of metastatic castration-resistant prostate cancer. By reanalysing published data on olaparib, talazoparib, rucaparib and niraparib, we provide a concise overview of responses by molecular subgroup. As monotherapy, all PARPi sh...
Daniel J. George, MD:PARP inhibitors have been around for a long time and one of the real advantages, even though this is a relatively new class of drugs to prostate cancer, [is that] we have a lot of experience in breast [and] ovarian cancer with these agents. The toxicity profile ...
Lurie Comprehensive Cancer Center, discusses the current role of PARP inhibitors in clinical trials for treatment of patients with prostate cancer.Maha H. Hussain, MB, ChB, professor of medicine and deputy director at Robert H. Lurie Comprehensive Cancer Center, discusses the current role of PARP ...
PARP (poly ADP-ribose polymerase) inhibitors have recently emerged as a new treatment option for metastatic castration-resistant prostate cancer (mCRPC) with a poor prognosis and are expected to contribute significantly to improving survival rates.Howeve
Breast Cancer|Ovarian Cancer|Pancreas Cancer|Prostate Cancer|BRCA1 Mutation|BRCA-Mutated Ovarian Carcinoma|BRCA-Associated Breast Carcinoma|HRD Positive Advanced Ovarian Cancer Tango Therapeutics Inc. December 8 2023Phase 1|Phase 2 References [1] Menear KA, et al. J Med Chem, 2008, 51(20), 6581...